Ira Pastor – Chief Executive Officer
Over 30 years of experience across multiple sectors of the pharmaceutical industry including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail; Served as VP, Business Development for drug development company Phytomedics Inc., raising $40 million of private equity, consummating over $50 million of licensing deals, and bringing lead drug candidate from discovery stage to Phase III development; Prior to that, employed by SmithKline Beecham Pharmaceuticals working in sales, marketing, and business strategy positions. Mr. Pastor has also served as Vice President of Corporate Development for the pharmacy benefit management company Prescription Delivery Systems (acquired by Cigna Health Insurance); MBA, Temple University; BS, Pharmacy, Rutgers University. He is also a Board Member of RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on expedited translational therapeutic applications of regenerative and rejuvenative healthcare interventions, the Reanima Project (http://www.reanima.tech), member of the Executive Council of WAMS, The World Academy of Medical Sciences, and member of the World Economic Forum’s Human Enhancement council.
Plants and human health in the twenty first century. – Trends Biotechnol. 2002 Dec;20(12):522-31.
Potential Threapeutic Applications of Extract Made from Electroporated Xenopus Laevis frog Oocytes in Murine Models of Melanoma, Traumatic Brain Injury and Experimental Skin Wrinkling – BAOJ Pharm Sci 2016, 2: 22: 024
Dr. Sergei Paylian – Founder, President, Chief Science Officer
Over 30 years of extensive research and administrative experience in the biomedical sciences including: molecular biology, genetics, immunology, immunohistochemistry, virology, experimental gerontology, oncology, pharmacology, microbiology, physiology, electrophysiology, and stem cell biology; Developed breakthrough technology in human somatic cell reprogramming (U.S. Patents pending), as well as precursor microincubator technology (Use of Xenopus laevis oocytes as microincubators – U.S. Patent #7,135,336); Held various academic research institute positions including: Department of Veterinary Medicine, University of Illinois, Urbana-Champaign, Illinois; College of Medicine, Bio-Sciences Department and Department of Pharmacology, University of South Florida, Tampa, Florida.; Department of Pediatrics, Division of Pulmonary Medicine, University of Wisconsin, Madison.; University of Illinois at Chicago, Chicago – MS, Ph.D (Hon) in Biophysics, Bogomolets Institute of Physiology, Kiev, Ukraine; MS in Physics, Biology and Chemistry, Department of Physical Science, Tbilisi State University, Republica of Georgia. He is also a Board Member of RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on expedited translational therapeutic applications of regenerative and rejuvenative healthcare interventions, and the Reanima Project (http://www.reanima.tech)
Arthur Finnel – Financial Controller
Mr. Finnel has more than 30 years of senior executive experience as both a General Manager and a Chief Financial Officer. His industry experience spans life sciences (drug development and nutraceuticals), consumer products (human food and pet foods), and agriculture. His financial expertise ranges in scope and size from large, private multinational firms (Mars, Incorporated) to angel and venture backed startups. He worked for 8 years as a public company CFO, including an IPO and taking a company private. Art possesses significant international experience in Canada, Europe, and Mexico. Mr. Finnel holds three degrees from the University of Pennsylvania—a Bachelor of Science degree in Economics from the Wharton School, a Master’s Degree in Operations Research, and a Wharton MBA in Finance.
Dr. Joel Isaias Osorio Garcia, MD – VP of International Development
Dr. Osorio brings over 20 years of experience in medical practice. Served in capacities in private and public practices, as hospital staff physician and as emergency health services coordinator for a variety of private and public institutions throughout Mexico and managed a blood bank from 2009- 2012. Earned MD degrees at Westhill University and the National Autonomous University of Mexico as a Medico Cirujano. In addition, has diplomas in aesthetic medicine from the Autonomous University of Guadalajara, as an Advance Fellow by the American Board of Anti-Aging and Regenerative Medicine, visiting scholar at University of North Carolina at Chapel Hill in dermatology. Fellow of Stem Cell Medicine by the American Academy of Anti-Aging Medicine and University of South Florida, and currently completing additional masters work in metabolic and nutrition sciences at University of South Florida and Master in Health Sciences Aged Services, Victoria University at Melbourne Australia. A member of the Round table of the ReGeNeRaTe laboratories Mexico’s Committee, a DNAge-Lab Company, working on the stem cells field since 2007, and since 2011 a member of the International Cellular Medicine Society. Chief Medical Officer & Co-Founder at Astrum Salud Móvil in Mexico City. PRP certified practitioner in the aesthetic and regenerative field since 2011 by GyCo. Speaker at the International Congress of the Western Clinical Research Institute in 2013. Appearing on different Mexican national TV programs and interviews as an anti-aging speaker and has also collaborated with different magazines writing related articles. Has conducted more than 4,000 PRP’s procedures, an expert in the use of antioxidants and BHRT, weight control (more than 400 patients with a high success rate), more than 200 patients implanted subcutaneously using human placenta derived stem cells, and over 350 cellular medicine treatments given for anti-aging purposes. Developed 3 different private practices at 3 different facilities in Mexico City in the past 4 years. He is also a Board Member of RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on expedited translational therapeutic applications of regenerative and rejuvenative healthcare interventions, the Reanima Project (http://www.reanima.tech), and member of the Executive Council of WAMS, The World Academy of Medical Sciences.
Risk factors associated with infections in peritoneal dialysis (CAPD). Rev Esp Med Quir 2006, 11 (3): 21-24
Dr. Antoinette Du Toit, MD – VP of Aesthetic Medicine
Dr. du Toit is an entrepreneur in the healthcare industry with over a decade of diverse professional experience in the field. She obtained her MBChB at the University of Pretoria in 2002. She furthered her studies in the management of diabetes at the Centre for Diabetes and Endocrinology in South Africa and also took various accredited courses in Aesthetic medicine and the application of stem cell therapies in the arena of aesthetics and clinical medical practices. Throughout her professional career, Dr. du Toit has consistently demonstrated passion vision, dedication and diligence necessary to experience great success in the entrepreneurial arena and in all of her professional endeavors. Drawing upon her wealth of knowledge in the field as well as her outstanding business acumen, Dr. du Toit is a medical doctor at her own aesthetic practice that specializes in cosmetic care and diabetology. She has also been an advisor to various aesthetic clinics in South Africa, sharing her knowledge, both in aesthetic procedures and clinic set-ups. Her comprehensive range of services covers botox, dermal fillers, chemical peels, mesotherapy, laser liposuction, stem cell therapies, PRP applications, lifestyle modification programs, detoxification and the management of diabetes, HIV and various other clinical diseases. Evidencing her remarkable reputation in the healthcare industry. Dr du Toit is member of the Aesthetic and Ant-aging Society of South Africa, Centre for Diabetes and Endocrinology, and Coschem. She is currently also advising government as to the application of new and revolutionary therapies.
Tatyana Reshetnikova, MS – Director, Production Operations
Ms. Reshetnikova has over 20 years of experience in the bioengineering sciences and medical technology. She has broad and outstanding cross-discipline knowledge of micro controllers, material science, biomechanics, engineering mathematics, medical instrumentation, linear control theory, signal processing, neural signal acquisition, biodesign, and engineering management. Ms. Reshetnikova constructed a short range, low frequency power transfer system to be implemented in implantable devices, specifically for the acquisition of neural recordings from rodents, as well as a grasping hand integrated with a Lynx motion robotic arm which was controlled using human bio-potential. Ms. Reshetnikova has an MS in Biomedical Engineering from the College of Industry and Technology, Bratsk, Russia.
David Gitlin / Greenberg Traurig – Corporate / Patent Counsel
Mr. Gitlin focuses his practice on corporate and securities, with an emphasis on mergers and acquisitions, venture capital, technology development, and corporate finance. For more than 30 years, David has counseled foreign clients doing business in the United States and U.S. clients doing business abroad. He has structured more than 200 M&A deals, more than half of which have been cross-border transactions involving leading businesses in Finland, India, Israel and Sweden, among others. He has represented U.S. clients in the purchase or sale of businesses in more than 15 countries.
Dr. Calixto Machado MD, PhD. – Special Advisor / Neurology / Disorders of Consciousness
Dr. Machado is President of the International Symposium on Brain Death and Disorders of Consciousness, President of the Cuban Society of Neurophysiology, and Senior Professor and Researcher at the Institute of Neurology and Neurosurgery, Havana, Cuba. Dr. Machado has spent over 20 years devoted to the topic of brain death and altered consciousness, authoring dozens of scientific papers and books, including most recently Brain Death: A Reappraisal
Dr. Melisa Cooper, MD – Nephrology / Clinical Pharmacology
Dr. Cooper brings over 17 years of pharmaceutical industry experience in Fortune 100 global healthcare organizations and biotech companies. Most recently, she served as VP Clinical Development of VIA Pharmaceuticals, designing innovative Phase I and Phase II clinical trials for novel atherosclerosis compounds. Prior to that, Dr. Cooper spent over fourteen years with Bristol-Myers Squibb, most recently as Vice President, Project Planning & Management, Pharmaceutical Research Institute. Dr. Cooper’s responsibilities with Bristol-Myers Squibb included evaluation and approval of drug development strategies and pivotal clinical trials, direction of strategic research activities, design and implementation of worldwide collaborative cardiovascular clinical studies, and responsibility for regulatory filings. Dr. Cooper earned her BA degree at the University of Pennsylvania, and her MD degree at the University of Pennsylvania School of Medicine. She continued her medical training at Emory University and Temple University, and also earned a MS degree in Clinical Pharmacology from Temple University School of Medicine. Dr. Cooper is Board Certified in Internal Medicine, and in Internal Medicine – Nephrology.
Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy – Kidney International (1996) 50, 1651–1658
Dr. Alejandro D. Mesples, MD – Clinical / Interventional Cardiology
Dr. Mesples completed his post-graduate basic training in Argentina and then in the Civil Hospital and Louis Pasteur University of Strasbourg in France and Bellvitge Hospital and University of Barcelona in Spain.
Currently, Dr. Mesples is the Director of Stem Cells Education and Research Institute, headquartered in Buenos Aires, Argentina. The Institute is an organization working in multidisciplinary teams that use a theoretical axis based on immunological and regenerative capabilities of platelet rich plasma and mononuclear cells (growth factors, lymphocytes, macrophages, platelets and stem cells). The Institute’s purpose is to conduct clinical investigations in cardiovascular disease, diabetes, joint and neurodegenerative diseases.
Dr. Nikolai Skiba, PhD – Ophthalmology
Assistant Professor of Ophthalmology, Duke Eye Center, Duke University School of Medicine; research interests include mass spectrometry based proteomics approaches to map proteins in retina layers, to identify new proteins involved in important biochemical processes of vision and also understand how misregulation of some proteins leads to eye diseases such as AMD and glaucoma
Proteasome overload is a common stress factor in multiple forms of inherited retinal degeneration – Proceedings of the National Academy of Sciences of the United States of America 2013;110(24):9986-91.
Proteomic identification of unique photoreceptor disc components reveals the presence of PRCD, a protein linked to retinal degeneration – Journal of proteome research 2013;12(6):3010-8.
A specific domain of Gialpha required for the transactivation of Gialpha by tubulin is implicated in the organization of cellular microtubules – The Journal of biological chemistry 2003;278(17):15285-90.